Case-Control Study for 23 Cancer Types With Functional Analysis of CHEK2: Risk Estimation and Clinical

Yuri Takehara1,2, Yoshiaki Usui1, Lenka Stolařová3

  • 1Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

JCO Precision Oncology
|September 2, 2025
PubMed
Summary

Germline damaging variants in the CHEK2 gene increase the risk of female breast and prostate cancer in East Asian populations. Standard cancer screening is recommended for CHEK2 variant carriers in this region.